Amgen AMGN announced that its regulatory application seeking label expansion for multiple myeloma treatment, Kyprolis, will be reviewed on a priority basis by the FDA. This means a response should be out by Jan 22, 2016. Kyprolis, which became
Forex – financial instrument.Forex news
Amgen AMGN announced that its regulatory application seeking label expansion for multiple myeloma treatment, Kyprolis, will be reviewed on a priority basis by the FDA. This means a response should be out by Jan 22, 2016. Kyprolis, which became